ITPRIPL1 and central nervous system cancer: Although ITPRIPL1 has been less studied in glioma, it has been reported in breast and lung cancers to influence therapeutic response by regulating immune checkpoint molecules, synergizing with PD-L1 to suppress T cell function, and recruiting M2 macrophages (Deng et al., 2023; Krasnyi et al., 2023).